Peggy Peck

UROLOGY ASSOCIATES OF DOVER

200 BANNING ST

SUITE 250

Articles

Drug-Eluting Stent Safety Triggers Special FDA Advisory Panel

September 14, 2006

ROCKVILLE, Md. -- The FDA said today that will convene a special meeting of an advisory committee to assess new data about "small but significant" increases in the rate of death and myocardial infarction among patients treated with drug-eluting stents.

Drug-Eluting Coronary Stents: Safety Concerns

September 14, 2006

ROCKVILLE, Md. -- The FDA said today that will convene a special meeting of an advisory committee to assess new data about "small but significant" increases in the rate of death and myocardial infarction among patients treated with drug-eluting stents.

Survey: Would You Still Recommend Drug-Eluting Stents?

September 11, 2006

Drug-eluting stents essentially eliminated short-term restenosis as a complication of coronary angioplasty, but suddenly the coated devices have come under a cloud for possible late term risks. This Medpage Today survey asks your opinion about the future use of drug-eluting stents. Additional Stent Coverage from ESC: Meta-Analyses Find Increased Death and MI with Cypher Stent Real World Trial Confirms Drug-Eluting Stents Better in Small Vessels Investigational Drug-Eluting Stent Superior to Taxus Drug-Eluting Stent Debate Develops Fever Pitch

ESC/WCC: World Congress of Cardiology Gets Call for Polypill for Secondary Prevention

September 03, 2006

BARCELONA, Spain -- The concept of a single pill packed with the potency of aspirin, statins, and ACE inhibitors-the triad proven to prevent a recurrent heart attack-got a powerful push at the opening of the World Congress of Cardiology here.

FDA Warns About Raw Pacific Northwest Oysters

August 02, 2006

ROCKVILLE, Md. -- The FDA has issued a nationwide warning to fans of raw Pacific northwest oysters to refrain from eating them raw, on pain of gastrointestinal distress, until the waters where they are harvested cool off.

FDA May Grant Restricted OTC Approval for PlanB

July 31, 2006

ROCKVILLE, Md. -- The FDA has suddenly signaled that it is ready, after three years, to move forward on limited over-the-counter status for Plan B, an emergency contraceptive. The move came the day before Andrew von Eschenbach, M.D., the acting FDA commissioner, is scheduled to testify before a Senate committee on his nomination as permanent FDA chief.

FDA Issues Warning About Super-Strength Hydrogen Peroxide

July 31, 2006

ROCKVILLE, Md. -- High-strength hydrogen peroxide, which is heavily marketed on the Internet for a diseases ranging from AIDS to emphysema, can cause serious harm or death when ingested, according to a warning issued by the FDA.

FDA Warns on Mixing Antidepressants with Migraine Drugs

July 20, 2006

ROCKVILLE, Md. -- Mixing common migraine drugs such as Imitrex (sumatriptan) with antidepressants like Prozac (fluoxetine) or Cymbalta (duloxetine) can trigger a life-threatening condition called serotonin-syndrome, the FDA has warned.

FDA Okays Gemzar-Paraplatin Duo for Recurrent Ovarian Cancer

July 17, 2006

INDIANAPOLIS -- The FDA has approved Gemzar (gemcitabine) in combination with Paraplatin (carboplatin) for treatment of recurrent ovarian cancer, Eli Lilly announced today.

FDA Okays Lucentis for Wet Age-Related Macular Degeneration

July 05, 2006

ROCKVILLE, Md. - The FDA has approved Lucentis (ranibizumab injection) for treatment of wet age-related macular degeneration.